High expression of transcription factor POU2F1 confers improved survival on smokers with lung adenocarcinoma: a retrospective study of two cohorts.
Non-small cell lung cancer (NSCLC)
Oct1
Pit-1, Oct1/2, Unc-86 (POU) domain class 2 transcription factor 1 (POU2F1)
adenocarcinoma
smoking
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
28 Apr 2023
28 Apr 2023
Historique:
received:
03
10
2022
accepted:
08
02
2023
medline:
18
5
2023
pubmed:
18
5
2023
entrez:
17
5
2023
Statut:
ppublish
Résumé
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide and its most important risk factor is tobacco smoking. While smoking is associated with inferior outcome in NSCLC patients, smoking also correlates with a higher tumor mutational burden. In contrast to adenocarcinomas (ADC) of non-smokers, that frequently harbor targetable gain-of-function mutations, NSCLC smokers largely present with non-targetable loss-of-function mutations of genes associated with DNA-damage repair. The transcription factor Pit-1, Oct1/2, Unc-86 (POU) domain class 2 transcription factor 1 (POU2F1) is a widely expressed bipotential stabilizer of repressed and inducible transcriptional states and frequently deregulated in cancer. Via immunohistochemistry, we evaluated POU2F1 protein expression on a tissue micro array of 217 operable stage I-III NSCLC patients. Findings were reproduced in a gene expression database of 1144 NSCLC patients, filtered for POU2F1 mRNA expression. After retroviral overexpression of POU2F1 in A549 cells, we evaluated for clonogenic growth and proliferation. Additionally, CRISPR-Cas9 mediated POU2F1 knockdown in A549 cells was likewise analyzed. High protein expression of POU2F1 in 217 NSCLC patients resulted in improved outcome of smokers with ADC [hazard ratio (HR) 0.30 (0.09-0.99), P=0.035]. Moreover, gene expression analysis confirmed favorable outcome of high POU2F1 mRNA expression in smokers with ADC [HR 0.41 (0.24-0.69), P<0.001]. Other than that, retrovirally induced overexpression of POU2F1 in A549 cells significantly reduced both, clonogenic growth as well as proliferation of NSCLC cells, whereas CRISPR-Cas9 mediated knockdown of the protein did not have any impact. Our data suggest that high expression of POU2F1 mediates a less aggressive cancer phenotype in smokers with ADC NSCLC. Pharmacological induction of genes and signaling pathways controlled by POU2F1 may provide novel avenues for future targeted NSCLC therapies in smokers.
Sections du résumé
Background
UNASSIGNED
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide and its most important risk factor is tobacco smoking. While smoking is associated with inferior outcome in NSCLC patients, smoking also correlates with a higher tumor mutational burden. In contrast to adenocarcinomas (ADC) of non-smokers, that frequently harbor targetable gain-of-function mutations, NSCLC smokers largely present with non-targetable loss-of-function mutations of genes associated with DNA-damage repair. The transcription factor Pit-1, Oct1/2, Unc-86 (POU) domain class 2 transcription factor 1 (POU2F1) is a widely expressed bipotential stabilizer of repressed and inducible transcriptional states and frequently deregulated in cancer.
Methods
UNASSIGNED
Via immunohistochemistry, we evaluated POU2F1 protein expression on a tissue micro array of 217 operable stage I-III NSCLC patients. Findings were reproduced in a gene expression database of 1144 NSCLC patients, filtered for POU2F1 mRNA expression. After retroviral overexpression of POU2F1 in A549 cells, we evaluated for clonogenic growth and proliferation. Additionally, CRISPR-Cas9 mediated POU2F1 knockdown in A549 cells was likewise analyzed.
Results
UNASSIGNED
High protein expression of POU2F1 in 217 NSCLC patients resulted in improved outcome of smokers with ADC [hazard ratio (HR) 0.30 (0.09-0.99), P=0.035]. Moreover, gene expression analysis confirmed favorable outcome of high POU2F1 mRNA expression in smokers with ADC [HR 0.41 (0.24-0.69), P<0.001]. Other than that, retrovirally induced overexpression of POU2F1 in A549 cells significantly reduced both, clonogenic growth as well as proliferation of NSCLC cells, whereas CRISPR-Cas9 mediated knockdown of the protein did not have any impact.
Conclusions
UNASSIGNED
Our data suggest that high expression of POU2F1 mediates a less aggressive cancer phenotype in smokers with ADC NSCLC. Pharmacological induction of genes and signaling pathways controlled by POU2F1 may provide novel avenues for future targeted NSCLC therapies in smokers.
Identifiants
pubmed: 37197633
doi: 10.21037/tlcr-22-714
pii: tlcr-12-04-727
pmc: PMC10183409
doi:
Types de publication
Journal Article
Langues
eng
Pagination
727-741Informations de copyright
2023 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-714/coif). The authors have no conflicts of interest to declare.
Références
Mech Dev. 2011 Sep-Dec;128(7-10):401-11
pubmed: 21854844
Respir Med. 2010 Dec;104(12):1767-74
pubmed: 20833010
Biochem Pharmacol. 2000 Jan 1;59(1):43-5
pubmed: 10605933
Oncogene. 2003 Oct 30;22(49):7762-73
pubmed: 14586402
Oncogenesis. 2015 Dec 21;4:e179
pubmed: 26690545
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008
Leuk Res. 2012 Aug;36(8):1028-34
pubmed: 22521726
Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12331-6
pubmed: 23836662
Mol Cell Biol. 2002 Nov;22(22):7769-79
pubmed: 12391146
Cell. 2012 Sep 14;150(6):1121-34
pubmed: 22980976
J Thorac Oncol. 2022 May;17(5):623-636
pubmed: 34995798
FASEB J. 2013 Jul;27(7):2807-17
pubmed: 23580612
Cancer. 2015 Sep 1;121 Suppl 17:3069-79
pubmed: 26331813
Oncotarget. 2017 Jul 4;8(27):44082-44095
pubmed: 28489585
J Thorac Dis. 2020 May;12(5):1824-1842
pubmed: 32642087
Cancers (Basel). 2022 Nov 04;14(21):
pubmed: 36358848
J Chin Med Assoc. 2013 May;76(5):249-57
pubmed: 23683257
J Appl Genet. 2020 Sep;61(3):421-437
pubmed: 32564237
Biochim Biophys Acta. 2016 Jun;1859(6):792-804
pubmed: 26877236
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Mol Cell Endocrinol. 2005 Jul 15;239(1-2):45-53
pubmed: 15885880
N Engl J Med. 2021 Jun 24;384(25):2371-2381
pubmed: 34096690
Crit Rev Oncog. 2011;16(1-2):129-40
pubmed: 22150313
J Biol Chem. 2001 Mar 30;276(13):9720-5
pubmed: 11134019
Ann Intern Med. 2021 Sep;174(9):1232-1239
pubmed: 34310171
PLoS One. 2013 Dec 18;8(12):e82241
pubmed: 24367507
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
Exp Hematol. 2019 Aug;76:38-48.e2
pubmed: 31295506
Cell Cycle. 2010 Oct 1;9(19):3933-44
pubmed: 20935455
Chin Med J (Engl). 2018 Aug 20;131(16):1904-1908
pubmed: 30082520
Cancer Res. 2005 Dec 1;65(23):10750-8
pubmed: 16322220
PLoS Genet. 2019 May 6;15(5):e1007687
pubmed: 31059499
Cancers (Basel). 2019 May 17;11(5):
pubmed: 31108964
Cancer Res. 2010 Dec 1;70(23):9671-81
pubmed: 21098706
J Thorac Oncol. 2021 Jan;16(1):162-168
pubmed: 33069888
Med Oncol. 2014 May;31(5):959
pubmed: 24722796
Nature. 1995 Jan 26;373(6512):360-2
pubmed: 7779176
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
EClinicalMedicine. 2021 Jun 26;38:100990
pubmed: 34505024
Oncogene. 2001 May 10;20(21):2683-90
pubmed: 11420680
Am J Respir Crit Care Med. 2016 Mar 1;193(5):534-41
pubmed: 26502000
Sci Rep. 2017 Mar 17;7:44744
pubmed: 28303973
Genes Dev. 2009 Jan 15;23(2):208-22
pubmed: 19171782
Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9772-9780
pubmed: 31799644
Diagn Pathol. 2014 Nov 29;9:221
pubmed: 25432701
Eur Respir J. 2018 Jul 11;52(1):
pubmed: 29853494
Am J Transl Res. 2021 Feb 15;13(2):672-683
pubmed: 33594317
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Med Oncol. 2022 Jul 19;39(10):152
pubmed: 35852645
Cancer Res. 2001 Feb 1;61(3):1187-95
pubmed: 11221850
Circ Res. 2003 Aug 22;93(4):e38-47
pubmed: 12881480
Oncol Rep. 2021 Mar;45(3):1295-1305
pubmed: 33469680
Cancer Sci. 2019 Nov;110(11):3476-3485
pubmed: 31454442
PLoS One. 2011;6(8):e23872
pubmed: 21897860
J Immunol. 2016 Apr 1;196(7):3159-67
pubmed: 26927796
J Biol Chem. 2011 Jan 7;286(1):450-9
pubmed: 21051540
Gastric Cancer. 2020 Mar;23(2):212-227
pubmed: 31463827
Anticancer Res. 2009 Jan;29(1):201-9
pubmed: 19331151
Ther Adv Respir Dis. 2016 Apr;10(2):113-29
pubmed: 26620497
Int J Cancer. 2020 Jun 1;146(11):3207-3218
pubmed: 31745979
Biochem Biophys Res Commun. 2020 Mar 5;523(2):354-360
pubmed: 31866012
PLoS One. 2015 Aug 27;10(8):e0136023
pubmed: 26313362
Am J Cancer Res. 2017 Aug 01;7(8):1665-1679
pubmed: 28861323
Bioinformatics. 2011 Nov 15;27(22):3206-8
pubmed: 21903630
Oncogene. 2007 Jun 7;26(27):3980-8
pubmed: 17213819
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
J Thorac Oncol. 2021 May;16(5):860-867
pubmed: 33476803
Mol Cell Biol. 2003 Dec;23(24):8934-45
pubmed: 14645506
Oncogene. 2019 Mar;38(10):1661-1675
pubmed: 30348992
N Engl J Med. 2010 Oct 28;363(18):1693-703
pubmed: 20979469
Mol Cell Biol. 1998 Jun;18(6):3416-30
pubmed: 9584182
Cancers (Basel). 2022 Mar 09;14(6):
pubmed: 35326547
Oncotarget. 2017 May 16;8(20):32731-32740
pubmed: 28415574
Lung Cancer. 2015 Feb;87(2):122-9
pubmed: 25534130